Trump needs to prove he's se­ri­ous about sci­ence; PTC's lat­est move is a jaw drop­per

End­points as­sess­es the big bio­phar­ma sto­ries of the week, with a lit­tle added com­men­tary on what they mean for the in­dus­try.

Two big steps back for the Trump ad­min­is­tra­tion

With Don­ald Trump in the White House, it’s al­ways one step for­ward and two steps back for bio­phar­ma. So last week we had Scott Got­tlieb’s nom for FDA com­mis­sion­er (a big step for­ward) fol­lowed by this week’s news that Trump’s bud­get plans to slash NIH spend­ing by close to $6 bil­lion, while dou­bling in­dus­try’s fees to the FDA (you guessed it.)

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE